At closing bell, the 225-issue Nikkei Stock Average rose 97.76 points, or 0.34%, to 28,958.56. The broader Topix index of all First Section issues on the Tokyo Stock Exchange declined 0.41 point, or 0.02%, to 1,956.73.
Trading volume turnover in the 1st section increased to 1,028 million shares from 994 million shares in previous session. Trading value turnover increased to 2,404.21 billion yen from 2,302.96 billion yen in previous session.
Total 20 sectors of 33 sectors sub-indexes on the Tokyo exchange ended lower, with Fishery, Agriculture & Forestry, Banks, Construction, Oil & Coal Products, Mining, Nonferrous Metals, and Air Transportation sectors being notable losers, while Marine Transportation, Pulp & Paper, Precision Instruments, Iron & Steel, and Glass & Ceramics Products issues were notable gainers.
Shares of drugmakers were up by reports of government support. Chugai Pharmaceutical and Ono Pharmaceutical both also ended stronger on reports that they will receive government subsidies for their research on Covid-19 drugs. Shionogi rose on reports that the firm plans to mass-produce its own Covid-19 vaccines.
Shares of pharmaceutical firm Eisai dropped after two straight sessions of gains by daily limit following the US approval of the Alzheimer's drug it developed with Biogen.
Kewpie shares advanced after a report said the Japanese mayonnaise maker has developed a vegan version of scrambled eggs that are made of soy beans.
CURRENCY NEWS: The U.S. dollar index, which tracks the greenback against a basket of its peers, was at 90.235 after recently bouncing from below the 90 level. The Japanese yen traded at 109.50 per dollar, weaker than levels around 109.2 against the greenback seen earlier this week.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
